<DOC>
	<DOCNO>NCT01656226</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety tolerability Eryfotona AK-NMSC® topical application v Sunscreen cancerization field actinic keratosis patient 6 month treatment .</brief_summary>
	<brief_title>Long Term Efficacy Safety Eryfotona AK-NMSC® Patients With Actinic Keratosis</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Sunscreening Agents</mesh_term>
	<criteria>1 . Current diagnosis AK , ≥4 lesion locate anatomical district ( within contiguous 50 cm2 area face , bold scalp forehead ) ; 2 . Female male &gt; 18 year age ; 3 . Skin type I II accord Fitzpatrick ; 4 . Patient confirm his/her willingness participate study ; . 1 . Topical drug therapy AK within past 3 month photoaging last 6 month , lesiondirected therapy within 2 cm2 select AK area previous month ; 2 . Suitable surgical , photodynamic topical treatment next 6 month ; 3 . Subjects suffer/ suffered skin cancer show early stage skin cancer genetic predisposition skin cancer ; 4 . Other skin disease require treatment medication treatment area distance 3 cm ; 5 . Immunosuppression current treatment cancer ; 6 . Clinically unstable medical condition ; 7 . High risk group HIV infection presentation infectious diseases 8 . Presentation contact allergy allergies compound test substance ; 9 . Smoker ( forty cigarette per day ) heavy drinker ( three standard drink per day ) ; 10 . Psychiatric disease may interfere follow study procedure ; 11 . Participation clinical trial 30 day prior day 1 study 12 . Prior treatment study medication area treat ; 13 . Considered investigator , reason , unsuitable candidate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Actinic Keratosis</keyword>
	<keyword>AK</keyword>
</DOC>